
Incidence and Treatment Costs of Severe Bacterial Infections Among People Who Inject Heroin
A Cohort Study in South London, England
Published in: Drug and Alcohol Dependence, Volume 212 (July 2020). doi: 10.1016/j.drugalcdep.2020.108057
Posted on RAND.org on May 19, 2020
Background
People who inject drugs often get bacterial infections. Few longitudinal studies have reported the incidence and treatment costs of these infections.
Methods
For a cohort of 2335 people who inject heroin entering treatment for drug dependence between 2006 and 2017 in London, England, we reported the rates of hospitalisation or death with primary causes of cutaneous abscess, cellulitis, phlebitis, septicaemia, osteomyelitis, septic arthritis, endocarditis, or necrotising fasciitis. We compared these rates to the general population. We also used NHS reference costs to calculate the cost of admissions.
Results
During a median of 8.0 years of follow-up, 24 % of patients (570/2335) had a severe bacterial infection, most commonly presenting with cutaneous abscesses or cellulitis. Bacterial infections accounted for 13 % of all hospital admissions. The rate was 73 per 1000 person-years (95 % CI 69–77); 50 times the general population, and the rate remained high throughout follow-up. The rate of severe bacterial infections for women was 1.50 (95 % CI 1.32–1.69) times the rate for men. The mean cost per admission was £4980, and we estimate that the annual cost of hospital treatment for people who inject heroin in London is £4.5 million.
Conclusions
People who inject heroin have extreme and long-term risk of severe bacterial infections.
Research conducted by
This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.